Loading the latest PSX data…
Loading the latest PSX data…
GlaxoSmithKline Pakistan LimitedShariah-compliantKSE-100
−1.10 (−0.32%) today
Live, checked 0s agoThe GlaxoSmithKline Pakistan share price was Rs 338.49 (−0.32%) at the last PSX update (Nov 17, 2026 10:49 AM). GLAXO is a pharmaceuticals stock in the KSE-100 index with a market value of Rs 107.8bn.
Last session's range16 Nov 2026
336.2052% up the range340.60
52-week range
293.0927% up the range459.27
Price limits (circuit breakers)
302.7253% up the range370.00
GLAXO ranks better than 89% of the 309 liquid PSX stocks we score. Each factor is a 0-100 rank (value is ranked half within pharmaceuticals). Education only, not a buy or sell signal.
−3.3% over 6M
Daily bars from PSX's end-of-day market summary; today's candle is provisional, from the live price (no volume until the close). Prices before a bonus issue, right issue or split are adjusted so the chart stays continuous; cash dividends are not taken out.
Full-screen GLAXO chart with levelsDownload GLAXO price history (CSV)Compare GLAXO with ABOT
From daily closes to 2026-11-16. A description of the trend, not a forecast.
Trend reading
Mixed
Down3 up · 2 down signalsUp
| S2 | S1 | Pivot | R1 | R2 |
|---|---|---|---|---|
| 334.40 | 336.99 | 338.80 | 341.39 | 343.20 |
+128.8% over 5 years
Monthly closing prices from the PSX Data Portal, since 2000. Earlier prices are adjusted for 11 bonus issues and splits (2000–2016; one share then is about 6.1 shares now) so the line shows the value of one original share.
| Announced | Period | Payout | Profit after tax | EPS (Rs) | Books close |
|---|---|---|---|---|---|
| 29 Oct 16:04 | 9 months to 30 Sept | None | Rs 7,191.1m | 22.58 | – |
| 25 Aug 15:39 | Half year to 30 Jun | First interim cash dividend 70% | Rs 4,580.6m | 14.38 | 3 Sept – 4 Sept |
| 28 Apr 12:06 | 1st quarter to 31 Mar | None | Rs 2,610.7m | 8.20 | – |
Measured from October 2021 to October 2026 using PSX daily closes.
For comparison, the KSE-100 (which includes reinvested dividends) returned about 30.5% a year over the same five years, an unusually strong period. Past returns do not predict future ones.
| Measure | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales growth | +7.7% | +23.2% | +18.7% | – |
| Profit growth | +53.4% | +1,124.1% | −78.3% | – |
| EPS growth | +53.4% | +1,121.4% | −78.3% | – |
| Net margin | 15.2% | 10.7% | 1.1% | 5.9% |
| Measure | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|---|
| Sales growth | +17.0% | – | – | – |
| Profit growth | +28.1% | – | – | – |
| EPS growth | +28.1% | – | – | – |
| Net margin | 15.7% | 13.6% | 15.3% | 14.4% |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales | Rs 65.9bn | Rs 61.2bn | Rs 49.7bn | Rs 41.8bn |
| Profit after tax | Rs 10.0bn | Rs 6.5bn | Rs 534m | Rs 2.5bn |
| Earnings per share (Rs) | 31.48 | 20.52 | 1.68 | 7.73 |
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|---|
| Sales | Rs 16.6bn | Rs 14.5bn | Rs 17.0bn | Rs 14.2bn |
| Profit after tax | Rs 2.6bn | Rs 2.0bn | Rs 2.6bn | Rs 2.0bn |
| Earnings per share (Rs) | 8.20 | 6.19 | 8.20 | 6.40 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Gross margin | 37.0% | 25.2% | 7.1% | 17.4% |
| Net margin | 15.2% | 10.7% | 1.1% | 5.9% |
| EPS growth | 53.4% | 1,121.4% | -78.3% | -54.0% |
| PEG | 0.23 | 0.02 | -0.63 | -0.21 |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report. Latest quarter (Q3 2026) EPS rose 28.1% from the same quarter a year earlier.
| Measure | GLAXO | Sector median | Reading |
|---|---|---|---|
| P/E | 9.8 | 12.4 | Cheaper than peers |
| Dividend yield | 6.1% | 4.7% | Above peers |
| Net margin | 15.2% | 8.8% | Above peers |
| EPS growth | +53.4% | +28.2% | Above peers |
| 1-year return | −13.9% | −12.7% | Below peers |
Sector P/E check. At the sector's median P/E of 12.4, last year's EPS of Rs 31.48 would price GLAXO at about Rs 389.14 (+15% from today). A rough yardstick only: sectors hold very different businesses, and the market prices future profits, not last year's.
Estimate a fair value for GLAXO (Graham, Lynch, DCF)GLAXO pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your GLAXO dividend income after tax
| Announced | Period to | Payout | Cash per share | Books closed |
|---|---|---|---|---|
| 25 Aug 2026 | 30 Jun 2026 | First interim cash dividend 70% | Rs 7.00 | 3 Sept 2026 – 4 Sept 2026 |
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
1st of 18
Rs 107.8bn
P/E (cheapest first)
2nd of 13
9.8
Dividend yield
2nd of 7
6.1%
1-year return
8th of 15
-13.9%
EPS growth
5th of 15
53.4%
Net margin
2nd of 16
15.2%
danioPSX score
1st of 13
89/100
| GLAXOThis stock · GlaxoSmithKline Pakistan Limited | Rs 107.8bn | −0.32% | 9.8 | 6.1% | −13.9% | 89 |
| ABOTAbbott Laboratories (Pakistan) Limited | Rs 98.4bn | +0.11% | 10.6 | 4.4% | −8.1% | 81 |
| HALEONHaleon Pakistan Limited | Rs 80.2bn | −0.68% | 12.3 | 3.6% | −15.7% | 67 |
| HINOONHighnoon Laboratories Limited | Rs 51.1bn | +0.75% | 12.4 | 5.4% | −15.4% | 76 |
| SEARLThe Searle Company Limited | Rs 47.1bn | +0.71% | 12.1 | – | −22.9% | 53 |
| AGPAGP Limited | Rs 43.7bn | +0.29% | 24.4 | 5.1% | −16.6% | 50 |
| HPLHoechst Pakistan Limited | Rs 38.4bn | −0.36% | 11.0 | 6.9% | −2.5% | – |
| FEROZFerozsons Laboratories Limited | Rs 15.9bn | −0.02% | 23.1 | 1.6% | −8.8% | 39 |
| CPHLCiti Pharma Ltd. | Rs 14.5bn | +0.14% | 17.9 | – | −21.6% | 31 |
| GSKCHGlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| BFBIOBF Biosciences Limited | Rs 12.0bn | −0.11% | 18.3 | – | −10.1% | 45 |
| MACTERMacter International Limited | Rs 11.8bn | −0.06% | 3.7 | – | −28.2% | 51 |
| SAPLSanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.7bn | +1.17% | 11.7 | – | +35.9% | 65 |
| LIVENLiven Pharma Limited | Rs 5.4bn | +10.00% | – | – | −9.0% | 11 |
Swipe the table sideways for more columns.
No director or substantial-shareholder trades in GLAXO read from PSX notices yet.
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
GlaxoSmithKline Pakistan Limited is incorporated in Pakistan as a limited liability company. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products. The Company is a subsidiary of S.R. One International B.V., incorporated in Netherlands, whereas its ultimate parent company is GlaxoSmithKline plc, UK (GSK plc).
Where the price sits in its 52-week range
Low 293.0927% of the way upHigh 459.27
Data: PSX Data Portal (Nov 17, 2026 10:49 AM); company data refreshed 17 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell GLAXO. Official PSX page for GLAXO